Drug Type Small molecule drug |
Synonyms Docirbrutinib, AS-1763, BN-102 + [1] |
Target |
Mechanism BTK C481S inhibitors(Bruton Tyrosine Kinase C481S inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC33H31FN6O3 |
InChIKeyLJODJUIHONTDMR-UHFFFAOYSA-N |
CAS Registry2227211-00-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
B-Cell Lymphoma | Phase 2 | CN | 01 Jul 2022 | |
Chronic Lymphocytic Leukemia | Phase 2 | CN | 01 Jul 2022 | |
Small Lymphocytic Lymphoma | Phase 2 | CN | 01 Jul 2022 | |
B-Cell Malignant Neoplasm | Phase 1 | US | 01 Aug 2023 | |
Follicular Lymphoma | Phase 1 | US | 01 Aug 2023 | |
Mantle-Cell Lymphoma | Phase 1 | US | 01 Aug 2023 | |
Marginal Zone B-Cell Lymphoma | Phase 1 | US | 01 Aug 2023 | |
Waldenstrom Macroglobulinemia | Phase 1 | US | 01 Aug 2023 | |
Diffuse Large B-Cell Lymphoma | Preclinical | JP | 22 Oct 2017 |
Phase 1 | - | uftiqqmwnd(rtucgcwztf) = gqoyqpwwpn urrczadgtp (erqqfljvvr ) | - | 15 Jun 2022 |